External quality assessment demonstrates that PD‐L1 22C3 and SP263 assays are systematically different

• Glavni autori: Andrew Dodson (Autor), Suzanne Parry (Autor), Birgit Lissenberg‐Witte (Autor), Alex Haragan (Autor), David Allen (Autor), Anthony O'Grady (Autor), Emma McClean (Autor), Jamie Hughes (Autor), Keith Miller (Autor), Erik Thunnissen (Autor)
• Format: Knjiga
• Izdano: Wiley, 2020-04-01T00:00:00Z.
• Teme: article
• Online pristup: Connect to this object online.

Abstract PD‐L1 inhibitors are part of first line treatment options for patients with advanced non‐small cell lung cancer. PD‐L1 immunohistochemistry (IHC) assays act as either a companion or a complementary diagnostic. The purpose of this study is to describe the experience of external quality assur...